Drug Profile
GSK 3378455A
Alternative Names: GSK-3378455ALatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Hepatitis C vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 23 Jul 2019 Discontinued - Phase-I/II for Hepatitis C (Prevention) in United Kingdom (unspecified route) (GlaxoSmithKline pipeline July 2019)
- 23 Jul 2019 Phase-I/II clinical trials in Hepatitis C (Prevention) in United Kingdom (unspecified route) before July 2019 (GlaxoSmithKline pipeline July 2019)